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Abstract
Biomarkers have the potential to improve diagnosis and prognosis, facilitate targeted treatment, 
and reduce health care costs. Thus, there is great hope that biomarkers will be integrated in all 
clinical decisions in the near future. A decade ago, the biomarker field was launched with great 
enthusiasm because mass spectrometry revealed that blood contains a rich library of candidate 
biomarkers. However, biomarker research has not yet delivered on its promise due to several 
limitations: (i) improper sample handling and tracking as well as limited sample availability in the 
pediatric population, (ii) omission of appropriate controls in original study designs, (iii) lability 
and low abundance of interesting biomarkers in blood, and (iv) the inability to mechanistically tie 
biomarker presence to disease biology. These limitations as well as successful strategies to 
overcome them are discussed in this review. Several advances in biomarker discovery and 
validation have been made in hematopoietic stem cell transplantation, the current most effective 
tumor immunotherapy, and these could serve as examples for other conditions. This review 
provides fresh optimism that biomarkers clinically relevant in pediatrics are closer to being 
realized based on: (i) a uniform protocol for low-volume blood collection and preservation, (ii) 
inclusion of well-controlled independent cohorts, (iii) novel technologies and instrumentation with 
low analytical sensitivity, and (iv) integrated animal models for exploring potential biomarkers 
and targeted therapies.
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1 Introduction
The identification and validation of biomarkers can contribute to major advances in the 
development of new therapies. The main types of biomarkers are diagnostic, predictive, and 
prognostic. They can be used to more accurately diagnose a disease, personalize treatment, 
identify novel targets for drug discovery, and enhance the efficiency of drug development. 
Biomarkers are identified through a wide range of approaches that include genetics, 
proteomics, immunomics, and metabolism. This review presents a viewpoint on biomarker 
development, discusses relevant analytical considerations, and provides a regulatory 
perspective summarizing a pathway toward biomarker validation.
Although written to encompass all aspects of biomarker discovery, validation, and 
qualification, this review centers on biomarkers of graft-versus-host disease (GVHD) due to 
recent advances in related biomarker development. Allogeneic hematopoietic stem cell 
transplantation (HSCT) is an increasingly widely used therapy in a range of malignant and 
non-malignant hematologic diseases. In allogeneic HSCT, the recipient immune and bone 
marrow systems are replaced by the donor immune and hematopoietic stem cells, with both 
positive and negative consequences. In malignant disease, the donor immune system can 
recognize residual leukemic cells as foreign and eradicate them by immunological means 
called the graft-versus-leukemia (GVL) effect. However , donor immune cells may also 
attack normal host tissue, particularly the skin, liver, and gastro-intestinal tract, resulting in 
the GVHD reaction [1]. The occurrence of GVHD remains one of the major barriers to more 
widespread and successful application of HSCT. Furthermore, a major barrier to GVHD 
research and treatment is that the diagnosis and prognosis rely almost entirely on the 
presence of clinical symptoms, which are sometimes confirmed by biopsy. Currently, no 
laboratory tests exist to predict the risk of developing GVHD, responsiveness to treatment, 
or patient survival. Despite these obstacles, considerable efforts have been made to develop 
GVHD biomarkers in a way that approaches used for GVHD biomarker discovery can now 
be consider as examples to follow. Indeed, the ability to identify patients at high risk for 
GVHD early in their transplantation and treatment course has important therapeutic 
implications, indicating when more stringent monitoring and/or preventative care will be 
beneficial. The ability to identify patients who will not respond to standard treatment and 
who are at particularly high risk for subsequent morbidity and mortality could result in 
personalized treatment plans, such as additional immunosuppressive treatments, that might 
be more effective if introduced early for high-risk patients. The identification of patients 
who will respond well to treatment could allow for more rapid tapering of steroid regimens, 
thereby reducing long-term toxicity and allowing a more robust GVL response in low-risk 
patients.
Paczesny et al. Page 2
Proteomics Clin Appl. Author manuscript; available in PMC 2015 March 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
The current review provides an update on the different types of biomarkers in the age of 
omics, the types of samples to be collected with a focus on the pediatric population, omics 
approaches for the discovery of circulating biomarkers, as well as a summary of successful 
approaches used to obtain biomarkers for acute GVHD.
2 Types of biomarkers in the age of omics
The NIH Biomarkers Definition Working Group defined a biomarker as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biologic processes, 
pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Biomarkers Definitions Working Group, NIH [2]). The Institute of Medicine further 
defined “objectively” to mean “reliably and accurately” [3]. Biomarkers are ideal for “high-
risk” translational studies involving mechanistically heterogeneous diseases [4] (add 
smoking cessation ref), with GVHD occurrence being a prime example.
Biomarkers have been evaluated in both hypothesis-driven and discovery-based testing for 
specific clinical outcomes. Initially, most biomarkers were identified from mechanistic 
studies and correlated with a particular outcome. Most recently, several groups have begun 
exploring omics biosignatures and biomarkers. Biomarkers can be classified into five types: 
(1) diagnostic, (2) predictive, (3) prognostic, (4) pharmacodynamic, which is a dynamic 
assessment showing that a biological response has occurred after a therapeutic intervention, 
and (5) surrogate disease, which is a substitute for a clinical endpoint. Due to the absence, so 
far, of studies investigating pharmacodynamic and surrogate markers correlated to GVHD, 
this review focuses specifically on the first three types of biomarkers, which may have the 
most significant short-term translational impact (Box 1).
3 Blood and plasma sample collection for molecular profiling
Success in molecular profiling is highly dependent on sample quality and standardized 
operating procedures. Some profiling technologies, such as those involving microRNAs, 
require relatively large sample volumes that may be a limiting factor in the pediatric 
population. Noninvasive clinical tests are to be preferred because it allows for repetitive 
sample collection from the same patient over a short period of time. Therefore, biofluids, 
such as plasma, sera, urine, or proximal fluids from an affected organ such as 
bronchoalveolar lavage (BAL) for lung are samples of choice. Effort has been made to 
develop standardized methods for clinical sample collection [5, 6]. The Human Proteome 
Organization (HUPO) Plasma Proteome Project specimen collection and handling report 
found that: (1) platelet-depleted plasma is preferable to serum for certain proteomic studies; 
(2) the addition of protease inhibitors should be incorporated early and used judiciously, as 
some form nonspecific protein adducts and others interfere with peptide studies (most 
plasma repositories to date do not add protease inhibitors); (3) diligent tracking is needed for 
pre-analytical variables, such as venipuncture vs. phlebotomy vs. from an existing line, 
tuning using a gel or non-gel separator, for plasma the nature of anticoagulant (EDTA, 
heparin, or citrate), processing time and protocols, storage conditions, and number of freeze/
thaw cycles; and (4) the use of reference materials for quality control and quality assurance 
also should be considered. These findings help provide guidance on sample handling issues, 
Paczesny et al. Page 3
Proteomics Clin Appl. Author manuscript; available in PMC 2015 March 16.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
with the overall recommendation that researchers must be conscious of all possible pre-
analytical variables as a prerequisite of any proteomic study.
Since most biorepositories have available plasma and sera, these are the biofluids most 
frequently analyzed. Unfortunately, plasma and sera contain many different proteins with a 
wide dynamic range, spanning twelve orders of magnitude from the most abundant to the 
lowest abundance protein. Clinically interesting proteins, such as cytokines and their 
receptors, are usually present in the lowest abundance [7, 8]. Detection of these low 
abundance proteins requires depletion of the predominant proteins and extensive 
fractionation of the proteome [9].
Urine and proximal biofluid samples [BAL, cerebrospinal fluid (CSF), saliva, etc.] represent 
alternatives to plasma and sera samples for biomarker identification. These samples are far 
less complex and can be obtained in large quantities. But, the limitations associated with 
their use are that they yield better information about diseases in the organs directly involved 
in their production and excretion, such as the kidneys, lung, brain, mucosa, etc., and often 
the samples are diluted and a method for normalizing the samples is required.
Peripheral blood mononuclear cells (PBMCs) have also been used by immunologists to 
discover cellular biomarkers and more recently immunomics as discussed below. 
Unfortunately, repositories do not always contain as many PBMCs as compared to plasma 
or sera.
Investigating markers in the damaged tissue itself could be more informative than screening 
systemic markers and therefore collection and banking of biopsies of GVHD target organs 
such as skin, intestine, liver, lung, and mucosa should be encouraged as often as possible. As 
mentioned above, good alternatives are biofluids of GVHD target organs such as bronchial 
lavage fluid (BAL) for the lung, saliva for the oral mucosa in the context of chronic GVHD, 
as recently published [10, 11].
Proteomic studies will be designed based on the availability of biofluids in biorepositories. 
Many individual transplant centers have established biorepositories to collect and store serial 
samples from patients at their centers. These are very useful for biomarker discovery efforts 
and initial validation of specific biomarkers. However, there has also been an effort to 
establish larger biorepositories associated with national multicenter trials. These 
biorepositories offer the great advantage that samples are collected from multiple centers 
and validations using these samples are therefore less likely to reflect center-dependent 
variables. Validations using these large multi-center repositories will be more likely to gain 
clinical acceptance and impact clinical practice. Of note, a limitation specific to the pediatric 
population is the limited volume available for serial blood collections. Thus, one future 
solution would be the use of dried blood/plasma spot cards, which allow for smaller sample 
volumes, are easier to handle, and are less expensive to transport and store. This approach is 
currently being explored [12], and we expect the use of such cards to be implemented in the 
next 5 years.
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4 Omics approaches for discovery of circulating biomarkers
Several omics approaches can be utilized for discovery of circulating biomarkers and are 
summarized below and in Figure 1 and Box 2.
1. Proteomic biomarkers
In this review, we focus specifically on the use of proteomics for the diagnosis of GVHD 
following HSCT, because proteins are more proximal to the ongoing pathophysiology of a 
disease [13]. The proteome varies with time and is defined as “the proteins present in one 
sample at a certain point in time.” Both non-mass spectrometry (MS)- and MS-based 
proteomic approaches have been employed to discover biomarkers. Antibody-based 
approaches rely on the unique properties of antibodies that can bind to an extremely wide 
range of molecules with exceptional binding specificity that enables the measurement of 
picomolar amounts of proteins in blood samples. On the other hand, MS-based approaches 
have become a powerful tool for characterizing and assessing both qualitative and 
quantitative changes in complex protein mixtures [14]. Several MS techniques are used in 
clinical proteomics: matrix-assisted laser desorption/ionization time of flight (MALDI-TOF) 
MS, liquid chromatography (LC) [9, 15–17], and capillary electrophoresis (CE) [18, 19]. 
These are gel-free methods that have several advantages over gel separation such as better 
separation of proteins with a low molecular weight and, shorter analysis time. Fractionation 
is followed by MS. This analytical procedure reliably identifies proteins and determines 
their isoforms and post-translational modifications. MS also allows quantification, especially 
when tandem MS (MS/MS) is used [20][9, 15, 21]. In addition, new instrumentation allows 
for better accuracy of the peptides identified [22]. The next step is the matching of mass 
spectra to a sequence database to identify peptides and proteins [23].
Although secreted proteins have been a fundamental source for biomarker discovery, it is 
important to note that protein biomarkers in serum and plasma often exist in multiple states 
and they may include multimers with different functional activity as well as states bound to 
other proteins. These different states are often not known or measured but may profoundly 
affect the clinical relevance of the measured biomarker. Recent efforts have been made to 
measure the functional states of proteins by identifying and understanding Protein post-
translational modifications (PTMs). PTMs increase the functional diversity of the proteome 
by the covalent addition of functional groups or proteins, proteolytic cleavage of regulatory 
subunits or degradation of entire proteins. These modifications include phosphorylation, 
glycosylation, ubiquitination, nitrosylation, methylation, acetylation, lipidation and 
proteolysis and influence almost all aspects of normal cell biology and pathogenesis. In 
addition, these PTMs result in number of protein variants (isoforms) showing micro 
heterogeneity of different kinds and high impact on the biological/ pathological function 
[24]. Proteomics approaches are also used for validation of candidate biomarkers. 
Immunoassays remain the assays of choice for validation, but high-quality antibodies pairs 
for sandwich enzyme-linked immunosorbent assay (ELISA) with the required affinities and 
specificities for the target are rare, leading to bias in the prioritization of candidate markers. 
ELISA assays are simple and highly reproducible between users and between laboratories, 
limiting both inter- and intra-assay variability. The two main disadvantages of validation by 
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ELISA are: 1) the large volume of patient plasma required, and 2) the bias introduced by 
selection of candidate biomarkers with commercially available ELISA kits. To overcome the 
first problem, multiplexing technology is preferred in the absence of cross-reactivity. To 
overcome the second problem, selected reaction monitoring-MS (SRM-MS) also called 
multiple reaction monitoring (MRM) is a potentially solution [25–28]. SRM-MS is used for 
targeted, multiplexed quantitative proteomics. Currently immunoassays are the standard for 
biomarker validation, but SRM may quickly a strong alternative, especially if 
recommendations from the NIH workshop addressing targeted peptide measurements in 
biology and medicine are implemented [29]. Furthermore, constrained SRM is ideal to 
quantify PTMs and isoforms [30].
2. Immunologic biomarkers
Immunomics is the study of immune system regulation in response to physiological or 
pathogenic processes. Unprecedented sophistication in instrumentation and software tools 
for human immunology studies have allowed researchers to visualize high-dimensional data 
in biological networks and evaluate the interrelationships between genes and/or proteins 
[31]. Recently, mass cytometry has addressed the analytical challenges of polychromatic 
flow cytometry by using metal atoms as tags rather than fluorophores as well as atomic MS 
as the detector instead of photon optics. The stable isotopes can provide up to 100 distinct 
tags that can be measured simultaneously in a single experiment. Using mass cytometry, the 
Nolan’s lab (Stanford) [32] were the first to show that perturbation of responses in 
individual cancer cells could be related to clinical outcomes in leukemia patients. An 
advantage of this single-cell approach is that signaling can be characterized in rare 
populations of cancer cells and compared with the bulk cancer cell population. The study 
from Stanford revealed and characterized the cell signaling heterogeneity of acute myeloid 
leukemia (AML) and showed that signaling in individual cancer cells can be closely linked 
to the clinical behavior of the disease [32]. Moreover, mass cytometry was applied to 
analyze differential immune responses to different drugs [33].
However, one of the most important obstacles facing research of the human immune system 
is the much greater inter-individual and intra-individual diversity compared with that of 
inbred mice. Experiments in animals infected with a particular virus and housed in 
pathogen-free facilities allow for detection of T cells expressing a particular T-cell receptor 
known to be specific for a particular virus epitope presented by a major histocompatibility 
molecule known to be expressed in that mouse strain. If the same experiment is now 
performed in humans, a whole new dimension of genetic and environmental complexity is 
added. Indeed, humans are outbred and thus express unknown combinations of human 
leukocyte antigen (HLA) molecules, and their environment is rich in pathogens. Therefore, 
individuals contain unknown varieties of T cells specific for unknown varieties of viral 
peptide-HLA complexes, requiring high-dimensional computational and technologic power. 
However, recent advances in single-cell evaluations, flow cytometry and high-throughput 
TCR sequencing mean that we now have improved access to the unique tools required to 
comprehensively analyze the adaptive T-cell immune responses in pediatric patients after 
HSCT [34].
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3. Metabolic biomarkers
The metabolome is defined as the full complement of small-molecule metabolites found in a 
specific cell, organ, or organism. Metabolomics is expected to have an impact in the areas of 
cancer, stem cell research, and the development of drug resistance. Relative to other omics 
measurements, metabolomics provides a more immediate and dynamic picture of the 
functionality of a cell. Furthermore, an important advantage of metabolomics is that unlike 
genomics and proteomics, humans and mice largely share the same metabolites. Therefore, 
identification of metabolic biomarkers in mouse and human samples relies on the same 
search engines. However, its use is currently limited to specialized laboratories because of 
the difficulty to measure the metabolome due to a fast reaction (seconds) to the environment, 
the large dynamic range of metabolites, the absence of amplification process, and the lack of 
fluorescent labeling without altering their normal function. MS is the analytical 
methodology of choice for identifying metabolites. It is likely that improvements leading to 
more complete coverage of the metabolome will emerge soon and that metabolomics will be 
part of our large collection of biomarkers in the near future, [35].
4. Nucleic acid-based biomarkers
Since the advent of next-generation sequencing (NGS) particularly DNA sequencing in 
2005, there has been severalstudies employing the technology to tackle previously 
intractable questions in many disparate biological fields. This has been coupled with 
technology development occurring at a remarkable pace. Hematologic malignancies are at 
the forefront of cancers whose genomes have been the subject of NGS. The first cancer 
genome to be sequenced by NGS was from a patient with a cytogenetically normal AML 
[36]. Multiple driver mutations have since been identified in AML and other hematologic 
malignancies such as myelodysplastic syndrome, myeloma, chronic lymphocytic leukemia, 
and solid cancers. These studies have opened novel areas of biology that can be exploited 
for prognostic, diagnostic, and therapeutic means.
Another important application of NGS is the study of the diversity of receptors that govern 
antigen recognition. Hence, we can now study normal and pathologic T and B cell 
repertoires, as well as monitor rare T-cell populations such as γδ T cells. This will allow, for 
example, an unprecedented depth of analysis of immune reconstitution following HSCT, 
which is particularly important in the pediatric population. Altogether, this increasingly 
affordable technology will undoubtedly impact future practice and care of patients with 
hematologic malignancies and following HSCT [37].
DNA analyses are not limited to findings of mutated DNA. Other strategies include 
quantification of methylated DNA or microRNAs (miRNAs). Hypermethylation of the CpG 
islands in the promoter region of tumor suppressor genes has been considered a contributing 
event in carcinogenesis via the silencing of suppressor gene transcription. Many of these 
targets are also found to be hypermethylated in the plasma of cancer patients and can serve 
as circulating biomarkers [38]. miRNAs are small (20–25 nucleotides) noncoding segments 
of RNA, such as that function by binding to mRNAs and regulating gene expression. 
Because they are released into the circulation and they are relatively resistant to degradation, 
miRNAs may be useful blood-based biomarkers [39, 40]. However, one limitation is that 
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current methodologies require a large volume of plasma to detect miRNAs. They have been 
evaluated in GVHD [41].
5. Circulating cells or DNA as tumor biomarkers
As noted above, circulating immune cells can be extensively phenotyped. Two technologies 
are currently used: (i) conventional flow cytometry measuring fluorescent labels [42, 43], 
and (ii) mass cytometry measuring metal probes with minimal signal overlap common to 
atomic MS [44].
Recently circulating tumor cells (CTCs) were identified and used as cancer biomarkers [45]. 
A number of techniques to capture CTCs have been developed using epithelial cell adhesion 
molecule (EpCAM) antibodies. Their role as early-stage cancer biomarkers is currently 
being explored [46, 47].
As noted in the previous paragraph, next generation DNA sequencing can also be used to 
detect and quantify tumor cells. This biomarker is being applied to quantify levels of 
minimal residual disease after stem cell transplantation as well as after other therapies. In 
this setting the target of sequencing can be rearranged B or T cell receptors in lymphoid 
malignancies or specific clonal mutations in other cancers [37].
6. Experimental models to discover biomarkers and as a tool for drug development
The paucity of biomarkers resulting from human-based discovery studies is due in part to 
the limited availability of appropriate quality biospecimens that overcome potential 
collection variability. The acquisition of human samples that are most pertinent to the 
intended clinical application represents another challenge. Particularly, samples that are the 
most relevant for early detection applications are difficult to obtain. However, blood and 
tissue collected at early stages of disease development would be readily available using 
experimental models including genetically engineered mouse models. This will allow 
discovery of biomarkers in relation to disease characteristics and over time. In addition, 
mice are maintained under conditions that minimize environmental biases [48, 49].
Animal models may also be used for drug development (Figure 2). Animal models can be 
utilized early, in the “target validation” stage of drug development, when studies are needed 
to understand the target and determine if it meets the criteria for a drug screen. Second, 
when pharmacologic agents are found, they can be tested in animal models to evaluate their 
potential efficiency and toxicity.
5 Computational analysis for high-dimensional data
Current datasets include many variables as well as multiscale data [different locations, types 
of molecules (proteins, miRNA, or cells, etc.), and time points]. Bayesian probability offers 
a statistical approach that captures the “causal” relationship between variables. Causal 
networks are constructed using conditional correlations based on “prior” information. 
“Priors” include data such as known protein-protein interactions, and transcription factor 
binding sites. Bayesian methods infer causal relationships between molecular relationships 
by randomly generating many possible network models and using statistical techniques to 
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select a consensus model that best fits the data [50]. Thus, these methods balance the trade-
off between prior knowledge and the data. Many of the software programs used to integrate 
high-throughput datasets are based on Bayesian principles [31]. These mathematical models 
based on networks interactions have also been referred to as ‘systems biology’. Systems 
biology build comprehensive, multiscale network models that accurately capture all of the 
regulatory elements of a biological system (e.g., immune system). Maps of potential 
connections among the variables are generated and may suggest new functional roles for 
specific genes, proteins, or metabolites. For biologists already focused on a particular 
molecule of interest, These analyses may potentially place a molecule of interest in the 
context of new pathways, molecular interactions, tissues, or diseases, allowing for new 
hypotheses to be tested. Predicted connections are then modified to test and validate the 
model through in vitro assays and in vivo experiments. This approach has also been used 
with datasets for small molecule drugs and allows for the discovery of repurposed drugs 
[51].
6 Statistical considerations
1. Framework for biomarker evaluation
Guidelines for reporting on diagnostic accuracy studies and prognostic studies have been 
proposed. The standards for Reporting of Diagnostic Accuracy (STARD) were published in 
2003 [52], and REporting recommendations for tumor MARKer prognostic studies 
(REMARK) were published in 2005 [53]. Recently, the Institute of Medicine (IOM) 
proposed a framework for biomarker evaluation that comprises three components [3]:
1) Analytical validity. This step requires analyses of the analytical performance of 
an assay. Performance characteristics include (i) precision (repeatability, 
reproducibility); (ii) accuracy; (iii) assay sensitivity (i.e., limit of detection); (iv) 
assay specificity (i.e., interference and cross-reactivity); (v) sample type and 
matrix; (vi) sample preparation and conditions; (vii) performance around the 
cutoff; and (viii) potential for carryover and cross-hybridization (mostly for 
multiplex technology).
2) Qualification.. This step requires assessment for associations between 
biomarkers and disease states, including data showing the effects of 
interventions on both the biomarker and clinical outcome.
3) Utilization. This step requires a contextual analysis based on the specific use 
proposed and the applicability of available evidence for this use. This includes a 
determination of whether the analytical validity and qualification conducted 
provide sufficient support for the use proposed.
The US Food and Drug Administration (FDA) has established a framework for biomarker 
development and qualification in the Center for Drug Evaluation and Research that is more 
stringent than the one proposed by the IOM [54, 55] (Figure 3). In the FDA framework, the 
biomarker is qualified for a specific “context of use”. A context of use is defined as a 
“comprehensive and clear statement that describes the manner of use, interpretation, and the 
purpose of a biomarker in drug development”.
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2. Statistical considerations
Several statistical methods can be used, and examples are summarized in Box 3 and detailed 
below. The target condition (condition of interest) refers to a well-defined clinical disorder 
such as a particular disease, a disease stage, or a condition that triggers a clinical action such 
as the beginning, modification, or termination of a treatment.
a. Diagnostic accuracy statistics
- Sensitivity. The sensitivity of a new test is estimated as the proportion of 
subjects with the target condition in whom the test is positive. For 
example, a sensitivity of 85% for a GVHD diagnosis test will correctly 
predict the presence of GVHD in 85% of patients tested.
- Specificity. The specificity of a new test is estimated as the proportion of 
subjects without the target condition in whom the test is negative. For 
example, a specificity of 85% for a GVHD diagnosis test will correctly 
predict the absence of GVHD in 85% of patients tested.
- Receiver operating characteristic (ROC) analysis. The ROC curve is a 
plot of the true-positive rate (sensitivity = 1 – false negative error rate) 
versus the false-positive rate (1 – specificity) for all possible thresholds 
[56, 57]. Whereas sensitivity and specificity can only be calculated with a 
defined threshold, the ROC curve can be used to calculate true and false 
positive rates for all possible thresholds[58].
- Positive predictive value (PPV). The proportion of patients with a 
positive test who have the target condition.
- Negative predictive value (NPV). The proportion of patients with a 
negative test who do not have the target condition.
b. Biased estimate
Abiased estimate is one that is systematically too high or low. Bias creates 
inaccurate estimates [59], and often the existence, size (magnitude), and direction 
of the bias cannot be determined. However, understanding potential sources of bias 
may help avoid or minimize bias.
c. Selecting the study population. Bias can be seen when a study does not include the 
complete spectrum of patient characteristics or when patient subgroups are missing. 
Thus, the “real world” performance of the test for the intended use has to be 
evaluated. If the study population is all inclusive, the test is likely to meet the 
validity criteria. Recommendations to satisfy external validity are to use the final 
version of the test, have multiple users with relevant training and expertise run 
several tests, and use a range of operating conditions.
d. Sample size. Statistical power and number of specimens that should be tested have 
to be determined before the study starts. Traditional sample size calculations have 
been challenged by Pepe et al. who proposed that computer simulations based on 
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biological models and number of cases and controls should determine the best 
sample size for the study in question [60].
7 Graft-versus-host disease biomarkers
All different types of biomarkers are represented in GVHD, as it is not only a systemic 
immunological disorder but it also affects specific organ systems such as the skin, 
gastrointestinal tract, and liver during the acute phase, and mucosa during the chronic phase. 
Several teams have discovered and validated circulating biomarkers relevant to HSCT in 
both hypothesis-driven and discovery-based testing. The data have come primarily from 
single centers or from a number of collaborating centers; in most cases, the findings have 
not been assessed as part of large multicenter trials. In Table 1, we summarized published 
GVHD biomarkers that were examined in more than one study and/or as a drug target and/or 
more than one cohort. Of this list, nine biomarkers (CXCL9, Elafin, HGF, IL-2Ra, IL-8, 
Keratin 18, Reg3α, ST2, TNFR1) [16, 17, 61–65] have been validated in an independent 
cohort using the same assay. Some are currently commercially available to clinicians with 
the limitation that thresholds for different clinical outcomes have still to be established in 
prospective collected samples. Details on the discovery and validation of these biomarkers 
were recently reviewed [66–69]. The next steps include evaluation of these biomarkers with 
samples collected in a multicenter cohort, which is necessary for reduction of center effects 
and the successful design of subsequent trials. This direction has already been taken by the 
Blood and Marrow Transplant Clinical Trial network that is currently acquiring prospective 
samples to validate thresholds and intend to pursue with therapeutic intervention for newly 
diagnose GVHD patients. This successful biomarkers identification, validation and 
implementation approach develop for GVHD could serve as an example for advances in 
other pediatric fields.
8 Conclusions
In a short-time, omics technologies have made tremendous progresses and have allowed 
identification of novel candidate biomarkers or molecular pathways. In the field of HSCT, 
the use of proteomics has led to the identification of novel biological mechanisms, which 
were unlikely to have been discovered by traditional hypothesis-driven research. Unlike 
gene expression levels, protein levels may be influenced by several post-transcriptional 
modifications and other factors, such as the cytokine milieu, requiring validation and 
qualification of biomarkers in different settings. Once a biomarker-based risk stratification 
algorithm is established, personalized medicine will be possible. In addition, the biomarker 
findings presented above offer the potential for exploring targeted therapeutics. Figure 4 
summarizes the workflow of the development of biomarkers from the bedside to the bench 
and back to the bedside.
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Figure 1. Assessment of circulating biomarkers through blood omics
A large number of high-throughput molecular and cellular profiling omics tools can be used 
to profile circulating biomarkers. Genomic approaches consist of determining gene sequence 
and function (for example, genome-wide association studies, RNA interference screens, 
exome sequencing, and methylation). Transcriptomic approaches consist of measuring the 
abundance of cellular or plasmatic RNA and also microRNAs present in cells or serum/
plasma. Cytomics is used to phenotype immune cells based on intracellular or extracellular 
markers using polychromatic flow cytometry or mass cytometry. Proteomics approaches are 
based on either multiplex antibody assays or mass spectrometry.
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Figure 2. US Food and Drug Administration (FDA) drug development tools (DDTs)
The DDT qualification Program, which includes biomarkers, was created by the Center of 
Drug Evaluation and Research to guide and prepare drug development efforts for rigorous 
safety and efficacy testing and eventual regulatory evaluation.
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Figure 3. Data from biomarker discovery (e.g., “omics” projects) can be used to focus further 
efforts along each step of validation to utilization
Biomarker development is interdependent. From discovery, a candidate biomarker is 
initially measured and analytically validated for its precision and accuracy. An optimal 
measure would be practical (e.g., robust and cost-effective) and easy to collect (e.g., 
noninvasive, measured with surrogate tissue such as saliva). A validated test is required 
before qualification, which is the linkage of the measure with its clinical outcome. Finally, 
independently corroborated qualification of biomarkers can be “utilized” for more general 
purposes.
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Figure 4. Workflow for the discovery, qualification, and implementation of new biomarkers
Samples (blood or plasma) are obtained from children diagnosed in the clinic with GVHD, 
ideally as dried spots in the near future. The proteins in the sample are subjected to 
separation and purification followed by MS/MS for protein identification. The protein 
concentrations from the patients’ samples are then compared to known concentrations of the 
identified protein in an immunoassay (usually sandwich ELISA). Once a biomarker is 
validated in a training and validation cohort and shows good sensitivity and specificity, its 
ability as a diagnostic, predictive, and/or prognostic tool is evaluated in clinical trials. 
Biomarkers may also offer important insights into the biology of a disease and identify 
novel pathways. Moreover, biomarkers may offer the potential for use in exploring targeted 
therapeutics. The end goal is more personalized treatment and improved patient outcomes.
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Table 1
Candidate GVHD biomarkers
Biomarker Studies No. of
patients in
studies
Role in GVHD
Proteomic biomarkers
α4β7 Integrin Chen 2009 [70] 59 Increased expression on naïve and memory T cells prior to 
intestinal
aGVHD.
Calprotectin Rodriguez-Otero 2012 [71]
Chiusolo 2012 [72]
72
68
Increased levels at the time of GI-GVHD diagnosis are 
predictive of
treatment responsiveness.
C reactive protein (CRP) Schots 2002 [73]
Pihusch 2006 [74]
Malone 2007 [75]
96
350
147
CRP levels reflect the risk of transplant-related mortality and 
major
transplant-related complications. Some studies show no 
difference
between aGVHD and other complications.
CXCL9* Croudace 2012 [76]
Kitko 2014 [61]
46
355
Plasma CXCL9 elevations correlate with chronic GVHD 
diagnosis and
a decrease in circulating CD4(+) cells expressing CXCR3 in 
the
blood, whereas increased in tissue biopsies of the dermis.
Elafina) Paczesny 2010 [17]
Levine 2012 [77]
522
112
Produced by keratinocytes. Increased concentrations at onset 
of skin
aGVHD.
Hepatocyte growth factor a) 
(HGF)
Okamoto 2001 [78]
Paczesny 2009 [62]
Harris 2012 [63]
Levine 2012 [77]
38
424
954
112
Increased in patients with aGVHD.
Interleukin (IL)-2Rα a) Miyamoto 1996 [79]
Foley 1998 [80]
Seidel 2003 [81]
Visentainer 2003 [82]
Shaiegan 2006 [83]
Paczesny 2009 [62]
August 2011 [84]
Levine 2012 [77]
30
36
60
13
67
424
62
112
Early post-transplantation levels are high prior to clinical signs 
of
aGVHD.
IL-6 Mohty 2005 [85]
Pihusch 2006 [74]
Malone 2007 [75]
113
350
147
Elevated at onset of aGVHD.
IL-7 Dean 2008 [86]
Thiant 2010 [87]
Thiant 2011 [88]
31
40
45
Levels increase significantly post-transplantation with an 
inverse
correlation to absolute T-cell count.
IL-8 a) Uguccioni 1993 [89]
Schots 2003 [90]
Mohty 2005 [85]
Paczesny 2009 [62]
Levine 2012 [77]
30
84
113
424
112
Early increase post-transplantation is associated with increased
mortality. Some studies show no difference between aGVHD 
and
other complications.
IL-18 Fujimori 2002 [91]
Shaiegan 2006 [83]
14
67
Correlates with the levels of IL-2Rα.
Keratin 18 a) Luft 2007 [64]
Luft 2011 [92]
Harris 2012 [63]
55
48
954
Increased levels during hepatic and intestinal aGVHD that 
correlate
with treatment unresponsiveness.
Regenerating islet-derived
protein 3α a)
Ferrara 2011 [16]
Levine 2012 [77]
1034
112
Released into circulation via GVHD-induced breaches of the 
mucosal
intestinal barrier. Elevated in GI-GVHD.
Suppression of
tumorigenicity 2
(IL-33 Rc) a)
Vander Lugt 2013 [65] 1054 Increased levels at initiation of therapy correlate with 
treatment
unresponsiveness and mortality. Elevation early post-
transplantation
(day 14) is associated with increased risk for death.
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Biomarker Studies No. of
patients in
studies
Role in GVHD
Tumor necrosis factor
(TNF)-α/ TNF-receptor 1 a)
Holler 1990 [93]
Abdallah 1997 [94]
Schots 2003 [90]
Mohty 2005 [85]
Choi 2008 [95]
Paczesny 2009 [62]
August 2011 [84]
Levine 2012 [77]
56
80
84
113
438
424
62
112
Elevation early post-transplantation is associated with severe 
aGVHD
and treatment-related mortality.
Peptide Sets Kaiser 2004 [18]
Weissinger 2007 [96]
Weissinger 2013 [19]
45
175
423
2013 study: aGvHD urinary proteomic classifier of 17 spectra
Cellular biomarkers
CD30 Hubel 2010 [97]
Chen 2012 [98]
30
53
Increased plasma levels and expression on T cells are 
associated with
the severity of aGVHD.
Dendritic cells (DCs) Lau 2007 [99]
Akhtari 2010 [100]
40
25
Decreased total blood DC count is associated with severity of 
aGVHD.
Invariant natural killer T 
(iNKT) cells
Chaidos 2012 [101]
Rubio 2012 [102]
57
71
Low iNKT/T cell ratio is associated with the occurrence of 
aGVHD.
Regulatory T cells Rezvani 2006 [103]
Wolf 2007 [104]
Magenau 2010 [105]
Koreth 2011 [106]
Di Ianni 2011 [107]
Matsuoka 2013 [108]
32
58
215
23
28
45
Levels are inversely correlated with the severity of aGVHD.
Examined in more than one cohort and/or more than one study and/or as a drug target
a)
Biomarkers using the same assay validated in an independent cohort
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